Hoth Therapeutics (NASDAQ:HOTH) Given Buy Rating at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Hoth Therapeutics (NASDAQ:HOTH) in a research report report published on Monday morning,Benzinga reports. The brokerage currently has a $5.00 price objective on the stock.

Separately, Wall Street Zen raised Hoth Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, July 5th. One analyst has rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Hoth Therapeutics currently has a consensus rating of “Buy” and an average target price of $4.00.

Hoth Therapeutics Stock Up 0.8%

Shares of HOTH opened at $1.29 on Monday. Hoth Therapeutics has a 12-month low of $0.65 and a 12-month high of $3.80. The business has a 50-day simple moving average of $1.29 and a two-hundred day simple moving average of $1.08. The stock has a market cap of $17.11 million, a PE ratio of -1.21 and a beta of 0.66.

Hoth Therapeutics (NASDAQ:HOTH) last issued its earnings results on Tuesday, August 12th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.10. On average, equities research analysts expect that Hoth Therapeutics will post -1.36 EPS for the current year.

Institutional Investors Weigh In On Hoth Therapeutics

A hedge fund recently raised its stake in Hoth Therapeutics stock. Geode Capital Management LLC raised its stake in Hoth Therapeutics, Inc. (NASDAQ:HOTH) by 8.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 122,575 shares of the company’s stock after buying an additional 9,071 shares during the period. Geode Capital Management LLC owned about 0.93% of Hoth Therapeutics worth $143,000 as of its most recent SEC filing. 7.08% of the stock is currently owned by hedge funds and other institutional investors.

About Hoth Therapeutics

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.